mapo Shares of Kyverna ( NASDAQ: KYTX ) tumbled 28% in morning trading Friday amid a presentation that included updated data for its lead CAR-T cell therapy candidate KYV-101. Kyverna made the presentation as part of an industry symposium at the EULAR 2024 rheumatology medical meeting in Vienna. The company included the presentation in an SEC filing on Friday.
Kyverna went public through an upsized IPO in February, raising $319M after pricing its shares above its previously proposed range. More on Kyverna Therapeutics, Inc. Historical earnings data for Kyverna Therapeutics, Inc.
Financial information for Kyverna Therapeutics, Inc..
